ang 1

Angiotensin (1-7) (ASP-ARG-VAL-TYR-ILE-HIS-PRO) is a synthetic heptapeptide identical to endogenous angiotensin-(1-7) , inhibits purified canine ACE activity (IC50=0.65 μM) with vasodilator and antiproliferative activities.

TRV120027 TFA is a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R) and engages ß-arrestins while blocking G-protein signaling.

Alamandine can be formed from angiotensin A by action of ACE-2 or directly from angiotensin-(1-7) by decarboxylation of its aspartate residue. The angiotensin A analog produces effects resembling those of Ang II (1-7). However, it acts independently of the two known vasodilators receptors of the RAS (Mas and angiotensin II type 2). To produce its effects, alamandine binds to the Mas-related receptor, MrgD. A novel orally active formulation of alamandine produced a long-term antihypertensive effect in spontaneously hypertensive rats and cardioprotective effects. These novel findings will be helpful for developing a new understanding of the RAS, a key regulator of blood pressure and fluid balance. The heptapeptide could serve as a model peptide, e.g. in the development and evaluation of analytical methods.

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA), is the primary circulating form of ANP in rats and significantly inhibits Ang II-stimulated secretion of endothelin-1.

Angiotensin 1-7 (Ang-(1-7)) acetate, an endogenous heptapeptide from the renin-angiotensin system (RAS), exhibits cardioprotective effects through anti-inflammatory and anti-fibrotic activities in cardiac cells. It inhibits purified canine ACE activity (IC50 = 0.65 μM) and modulates kinin-induced vasodilation by hindering ACE and facilitating nitric oxide release. This compound also prevents Ang II-induced proliferation and hypertrophy in smooth muscle cells and demonstrates antiangiogenic and growth-inhibitory effects on the endothelium [1] [2] [3].

Norleual TFA, an analog of angiotensin (Ang) IV, functions as a hepatocyte growth factor (HGF)/c-Met inhibitor, displaying a potent inhibition capability with an IC50 of 3 pM. Additionally, it acts as an AT4 receptor antagonist and demonstrates significant antiangiogenic activities [1].